Schizophrenia
Therapeutic Market, by Treatment (First Generation Antipsychotic Drugs and
Second Generation Antipsychotic Drugs), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook,
and Opportunity Analysis, 2018 – 2026
Schizophrenia is a mental
disorder where the patient suffers from inability to understand the reality,
decreased ability of thinking, abnormal behavior, and strange speech.
Furthermore, the patient suffers from reduced emotional expression, anxiety,
depression or less social engagement. According to the Brain & Behavior
Research Foundation, schizophrenia generally occurs between the ages of 16-30.
Although the main cause of schizophrenia is unknown, possible reasons are
genetic, environmental factors or poor nutrition during pregnancy.
Treatment for schizophrenia
include, psychological therapies, behavioral therapies, and antipsychotic
drugs. Electroconvulsive therapies also aid in the treatment of schizophrenia.
In severe cases, hospitalization is necessary for a short period of time.
Global Schizophrenia Therapeutic
Market Drivers
The global schizophrenia
therapeutic market size is expected to expand, owing to increasing prevalence
of schizophrenia. In 2018, World Health Organization (WHO) reported that over
23 million patients were affected by schizophrenia worldwide. Furthermore,
increasing approvals of therapies with second generation antipsychotic drugs
such as Risperidone, Paliperidone, Olanzapine, and Lurasidone, which have less
side effects is also expected to drive the global schizophrenia therapeutic
market revenue. For instance, in 2015, the U.S. Food and Drugs Administration
(FDA) approved Vraylar (Cariprazine), which was tested on 1,750 patients. The
drug showed effective reduction of symptoms in schizophrenia in less time.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2468
Global Schizophrenia Therapeutic
Restraints
The common negligence and stigma
regarding schizophrenia is one of the major restraining factors for hampering
the schizophrenia therapeutic market growth. For instance, in 2018, the
Schizophrenia and Related Disorders Alliance of America (SARDAA) reported that
around 50% of people diagnosed with schizophrenia do not receive treatment,
owing to negligence for mental health.
Moreover, the side effects caused
by antipsychotics such as weight gain, dizziness, restlessness, nausea, blurred
vision, low blood pressure, seizures, and constipation can also be negative
growth rendering factor for the global schizophrenia therapeutic market
revenue. For instance, according to National Centre for Biotechnology
Information (NCBI) 2017 findings, obesity is affecting 15%-72% patients, 12% of
patients are suffering from diabetes, and the prevalence of constipation is 39%
in schizophrenic patients. Consumption of antipsychotics may also lead to sudden
cardiac death and ventricular arrhythmia.
Global Schizophrenia Therapeutic
Market Regional Analysis
North America holds dominant
position in the schizophrenia therapeutic market, owing to increasing
incidences of schizophrenia and high investment in schizophrenia therapy in the
region. According to SARDAA, around 3.2 to 3.5 million people in the U.S. were
suffering from schizophrenia in 2013.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/schizophrenia-therapeutic-market-2468
According to the same source,
around US$ 32 to US$ 65 billion are annually spent on treatment and other
economic costs of schizophrenia in the U.S.
Asia Pacific is fastest growing
region in schizophrenia therapeutic market due to high prevalence of
schizophrenia in economies such as China and India. According to NCBI 2014
data, prevalence of schizophrenia in China was 4.62 per 1000 people.
Schizophrenia therapeutic market size is also expected to boost due to launch
of new medicines in China. For instance, Janssen Pharmaceutical Companies of
Johnson & Johnson launched INVEGA TRINZA in 2018 for the treatment of schizophrenia
in China. INVEGA TRINZA is a three-month long-acting atypical antipsychotic
drug for insomnia.
Global Schizophrenia Therapeutic
Market Key Players
Key players operating in the
global schizophrenia therapeutic market include, AstraZeneca, Bristol-Myers
Squibb, Eli Lilly and Company, Johnson & Johnson, Pfizer, Sandoz Canada
Inc., Intas Pharmaceuticals, Novartis AG, Otsuka Pharmaceuticals, Alkermes,
Allergan (Forest Labs), and Sumitomo Dainippon Pharma.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2468
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment